Wolfgang Miesbach: Rebalancing Agents in Haemophilia Are Not “Set and Forget” – Key Insights from WFH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared posts on LinkedIn, highlighting key insights from the World Federation of Hemophilia (WFH) 2026 Congress։
”Rebalancing agents are not ‘set and forget’
Excellent presentation today by Alok Srivastava at the Sanofi industry symposium during WFH Congress Kuala Lumpur on rebalancing agents in haemophilia – showing how different targets (TFPI leads to concizumab / marstacimab; AT leads to fitusiran), loading doses and maintenance intervals (QD / QW / Q2M) demand truly individualised dosing strategies.
- Traditional assays (PT / aPTT) largely unaffected
- PK/PD (where available) help to fine‑tune dose / frequency to maintain target range
- Global assays (TGA / TEG / ROTEM) could be useful in selected settings (e.g. peri‑operative management)
- All dosing decisions embedded in shared decision‑making, patient goals, comorbidities, thrombosis risk
A timely reminder that optimising dose and monitoring is now central to safe and effective haemostatic rebalancing.”
”In the rebalancing era, proactive, protocol‑driven management of any breakthrough bleed has become a fourth pillar of haemophilia care – alongside prophylaxis, monitoring and shared decision‑making.
Interesting summary of treatment recommendations for breakthrough bleeds under rebalancing agents, presented by Alok Srivastava at the Sanofi industry symposium during the WFH Congress in Kuala Lumpur.
- Patient population: haemophilia A/B, ± inhibitors
- Product choice: FVIII/FIX (standard or EHL), aPCC, rFVIIa
- Principle: use the lowest effective dose
- Interval before repeat dosing: typically 24 h vs 5–7 d, depending on product
- Antifibrinolytics: allowed, used with caution or avoided with certain agents.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand